Gilead Sciences launched a clinical trial in the Democratic Republic of Congo for an experimental antiviral. The treatment targets the Bundibugyo strain of Ebola, a virus known for high fatality rates.
This trial expands the company's infectious disease pipeline beyond its established HIV and Hepatitis treatments. Positive results could establish a new tool for global Ebola outbreak responses. Market reaction to the news has not yet been widely reported.